FDA decision: Rusfertide by Protagonist Therapeutics (in 2026)

FDA decision on Rusfertide in 2026 If the FDA's decision on Rusfertide by Protagonist Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Rusfertide, developed by Protagonist Therapeutics and licensed to Takeda, is a peptide drug designed to treat polycythemia vera (PV), a blood disorder